Drug Profile
NHWD 870
Alternative Names: NHWD-870Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Ningbo Wenda Pharma
- Class Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors; Mitogen-activated protein kinase inhibitors; Platelet-derived growth factor beta receptor modulators; Platelet-derived growth factor inhibitors; Proto oncogene protein c-myc inhibitors; Proto-oncogene protein inhibitors; STAT1 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Cancer in China
- 01 Apr 2017 Preclinical trials in Cancer in China
- 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)